p21 activated kinase-1 and tamoxifen – A deadly nexus impacting breast cancer outcomes
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Genetics,Oncology
Reference123 articles.
1. Tamoxifen: catalyst for the change to targeted therapy;Jordan;Eur. J. Cancer,2008
2. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer;Jordan;Endocr. Relat. Cancer,2014
3. Tamoxifen a pioneering drug: an update on the therapeutic potential of tamoxifen derivatives;Shagufta;Eur. J. Med. Chem.,2018
4. Risk reduction strategies in breast cancer prevention;Costa;Eur. J. Breast Heal.,2017
5. Mechanisms of tamoxifen resistance;Ring;Endocr. Relat. Cancer,2004
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Activation of oncogenic signaling kinase PAK1 by ionising radiation confers an aggressive phenotype in head and neck squamous cell carcinoma;Cellular Signalling;2023-12
2. The effect of DDIT3 on luminal A type breast cancer;2023-11-28
3. PAK1 copy number in breast cancer—Associations with proliferation and molecular subtypes;PLOS ONE;2023-06-27
4. An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management;Journal of Personalized Medicine;2023-04-28
5. Hyperactivation of p21-Activated Kinases in Human Cancer and Therapeutic Sensitivity;Biomedicines;2023-02-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3